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Abstract 
Background: Diabetes and tobacco smoking are significant public health concerns which have been shown to 
independently impact the blood–brain barrier (BBB). Since smoking is a risk factor for diabetes and shares some of the 
common pathological pathways leading to metabolic abnormalities, it is hypothesized that their combination would 
produce additive or synergistic BBB dysfunction. Therefore, the objective of this study was to assess this hypothesis 
and evaluate the magnitude of these effects in vitro using hCMEC/D3 cells; a well-established human BBB endothelial 
cell line.
Methods: Monolayers of hCMEC/D3 cells were exposed to hyperglycemic conditions (HG; 35 mM) or 5% soluble 
cigarette smoke extracts (CSE, model of mainstream smoke exposure) for 12–24 h. Cells were then harvested for sub-
sequent biochemical analyses. Transendothelial electrical resistance (TEER) and paracellular permeability to florescent 
dextrans were used to assess monolayer integrity. Analysis of released factors and cytokines was carried out by ELISA. 
Western blot (WB) analysis/immunofluorescence of relevant molecular targets was carried out. P-gp efflux activity was 
measured using rhodamine 123.
Results: Immunofluorescence and WB data showed a significant ZO-1 down-regulation by HG and/or CSE over 24 h 
exposure. CSE in presence of HG produced a synergistic increase in release of vascular endothelial growth factor that 
was accompanied by decreased TEER and augmented permeability to labeled dextrans in a size-dependent manner. 
Moreover, CSE increased the expression of GLUT-1 and SGLT-1 in isolated membrane fractions of hCMEC/D3 cells. The 
effect was amplified by HG. Both, HG and CSE elicited the membrane upregulation of P-glycoprotein (P-gp) expres-
sion which however, was not paralleled by a comparable efflux activity. Interestingly, concomitant exposure to HG 
and CSE evoked a marked upregulation of PECAM-1 and other pro-inflammatory markers including IL-6 and -8, when 
compared to each condition alone. Moreover, exposure to all tested conditions amplified (to a different degree) cel-
lular oxidative stress response denoted by increased Nrf2 nuclear translocation.
Conclusion: Overall, our results have clearly shown an additive pattern in the release of angiogenic and inflamma-
tory factors following concomitant exposure to HG and CSE. This suggests the involvement of common key modula-
tors in BBB impairment by both CS and HG possibly through the activation of oxidative stress responses.
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Background
Cigarette smoking accounts for 434,000 casualties/year 
in US and is the leading cause of preventable death. Even 
though there has been a marginal decline in smoking in 
recent years, the fact that ≈18% of the US adult popula-
tion are current smokers is alarming [1]. In 2007 diabe-
tes was the 7th leading cause of death in the US and it 
is increasing at an alarming rate. One in every three US 
adults are projected to suffer from diabetes by 2050 [2]. 
Smoking is a major risk factor for diabetes [3], with 12% 
of type-2 diabetes mellitus (2DM) cases being attributed 
to tobacco smoke [4]. Both active and passive smoking 
not only causes glucose intolerance [5], but significantly 
increases the risk of diabetes by 45 or 74% in men and 
women, respectively [6]. Major pathological changes 
in diabetic patients such as insulin resistance and high 
levels of glycated hemoglobin (HbA1c) have also been 
reported in smokers [7]. Both 2DM and smoking have 
been reported independently to enhance the risk of cer-
ebrovascular and neurological disorders like stroke [1, 
8], Alzheimer’s [9, 10], depression [11, 12], cognitive 
impairment, and vascular dementia [13, 14]; largely due 
to an increase in reactive oxygen species (ROS) genera-
tion [15–17], proinflammatory activity [18, 19], and BBB 
impairment [20, 21]. However, 2DM and CS—depend-
ent pathophysiological mechanisms underlying these 
cerebrovascular disorders remain elusive. CS contains 
over 4,000 chemicals including nicotine and various ROS 
(e.g., H2O2, epoxides, nitrogen dioxide, peroxynitrite—
ONOO−, etc. [22, 23] ) which pass through the lung 
alveolar wall and raise systemic ROS [24]. At the cer-
ebrovascular level this promotes oxidative damage and 
BBB breakdown via tight junction (TJ) modification and 
activation of proinflammatory pathways [25, 26]. Chronic 
hyperglycemia, a pathogenic alteration characteristic of 
2DM, also causes endogenous ROS increase by inhibit-
ing glycolysis and promoting the formation of harmful 
intermediates such as advanced glycation end products 
(AGEs) and protein kinase-C pathway (PKC) isoforms, 
which have DNA and protein damaging effects [27, 28]. 
At the BBB level, chronic hyperglycemia causes endothe-
lial dysfunction leading to BBB impairment and loss of 
barrier integrity [28].
Similarly, chronic hyperglycemia has also been 
reported to alter the expression of a number of BBB 
functional transporters including facilitative sodium 
independent glucose transporter-1 (GLUT-1), sodium 
dependent glucose co-transporter-1 (SGLT-1) and P-gly-
coprotein (P-gp) [28]. However, the reports are contro-
versial with certain studies reporting a decrease [29, 30] 
or no change [31–33] in cerebral GLUT-1 and SGLT-1 
protein expression, and an increase [34] or unaltered 
[33] local cerebral glucose utilization. In addition, P-gp 
expression levels have been reported to decrease [35, 36], 
increase [37] or remain unaffected [38] in animal diabetic 
models. Expression and activity changes of P-gp at BBB 
on smoke exposure have not yet been investigated. Fur-
ther, despite the epidemiological and translational studies 
strongly suggesting activation of similar pathophysiologi-
cal pathways by 2DM and CS, determination and charac-
terization of shared key modulators in BBB impairment 
lies unexplored. Identification and then targeting of these 
putative key modulators could help in preventing the 
initiation of metabolic/cerebrovascular complications in 
smokers.
Therefore, the objective of our study was to investigate 
the individual and combinatorial effects of tobacco prod-
ucts and hyperglycemia on BBB endothelium. The experi-
ments were conducted in vitro using a well-characterized 
human BBB endothelial cell line hCMEC/D3 [39]. Data 
from this study indicates that hyperglycemia and tobacco 
smoke (TS) exposure cause dysfunction of BBB endothe-
lium (e.g. impaired tight junction protein expression/
distribution, increase in permeability, increase in proin-
flammatory activity, etc.). Further, our results suggest the 
existence of similar patterns of endothelial dysfunction in 
response to TS and hyperglycemia which shows additive 
or synergistic effects in the majority of our experimental 
scenarios. Together our data suggest the involvement of 
shared pathological pathways in TS and hyperglycemia 
which impact the BBB.
Methods
Antibody sources
The antibodies used in this study were obtained from 
the following sources: rabbit anti-ZO-1 (#D7D12), rab-
bit anti-ICAM-1 (#4915S) and mouse anti-PECAM-1 
(#89C2) from Cell Signaling Technology (Danvers, MA, 
USA); mouse anti-occludin (#331500) from Life Tech-
nologies (Grand Island, NY, USA); mouse anti-glut-1 
(#MABS132) and mouse anti-P-gp (517301) from EMD 
Millipore (Billerica, MA, USA); rabbit anti-SGLT-1 (#ab-
14686) from Abcam (Cambridge, MA, USA); rabbit anti-
Nrf2 (#sc-722) from Santa Cruz Biotechnology (Santa 
Cruz, CA, USA); β-actin (#A5441) from Sigma-Aldrich 
(St. Louis, MO, USA); donkey anti-rabbit (#NA934) 
and sheep anti-mouse (#NA931) HRP-linked second-
ary antibodies from GE  Healthcare (Piscataway, NJ, 
USA); goat anti-rabbit (#A11008, A21428) conjugated to 
Alexa Fluor® 488 and 555, respectively and anti-mouse 
(#A11001) conjugated to Alexa Fluor® 488 from Invitro-
gen (Camarillo, CA, USA).
Reagents
Sterile culture ware was obtained from Fisher Scientific 
(Pittsburgh, PA, USA), reagents and chemicals were 
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purchased from Sigma-Aldrich or Bio-rad laborato-
ries (Hercules, CA, USA), while Mini-Protean® TGX™ 
gels 4–15% (#456-1084) from Bio-rad laboratories was 
used for gel electrophoresis. Dextran-Cascade Blue® 
(10,000 MW; #D-1976) was obtained from Life Technol-
ogies, while Fluorescein isothiocyanate (FITC)-dextran 
(3,000–5,000  MW; #FD4) and Rhodamine B isothiocy-
anate (RITC)—dextran (70,000 MW; #R9379) were pur-
chased from Sigma-Aldrich.
Tobacco smoke preparation
Cigarettes (3R4F) equivalent to full flavor commercial 
brands with 9.4 mg tar and 0.726 mg nicotine per ciga-
rette were obtained from the University of Kentucky. 
Cigarette smoke extracts (CSE) was prepared by bub-
bling eight puffs per cigarette directly into phosphate 
buffered saline (PBS). This was done in accordance to 
the ISO/FTC standard smoking protocol (draw of 35 ml, 
puff duration of 2 s, 1 puff per 60 s), using a single ciga-
rette smoking machine (SCSM, CH Technologies Inc., 
Westwood, NJ, USA). A 3× concentration (or 300%) of 
stock solution was first prepared by using three ciga-
rettes. It was then diluted to 5% concentrations in low 
serum media depending upon the treatment conditions 
as described later.
Cell culture
The immortalized hCMEC/D3 endothelial cell line was 
obtained from Dr. Couraud (INSERM, Paris). These 
hCMEC/D3 cells (passages no. 28–30) were seeded on 
collagen-coated cell culture flasks or glass chamber slides 
(seeding density of 2.5  ×  104/cm2) and maintained at 
37°C with 5% CO2 exposure. Cell culture medium con-
sisted of EBM-2 basal medium (Lonza, Walkersville, MD, 
USA), which was supplemented with 5% FBS (Atlanta 
Biologicals, Lawrenceville, GA, USA), Fibroblast Growth 
Factor (Sigma Aldrich), chemically defined lipid con-
centrate (Life Technologies, Carlsbad, CA, USA), anti-
biotic/antimycotic (1:1, Atlanta Biologicals, GA, USA) 
and HEPES (10 mM). The culture medium was changed 
every other day until the cells reached confluency. Phase 
contrast microscopy and the expression of characteristic 
phenotypic markers confirmed the monolayer integrity 
of the hCMEC/D3 cells at confluency.
Transwell cell culture setup
Clear polyester transwell inserts (0.4 µm pore size mem-
branes) were seeded with hCMEC/D3 cells (passage no. 
28–29) on the luminal side and grown in the culture 
medium containing EBM-2 basal media and supplements 
as mentioned above. The wells were coated with collagen 
prior to seeding. Trans-endothelial electrical resistance 
(TEER) measurement and phase contrast microscopy 
was employed to confirm cell layer confluency and 
integrity.
Treatment
HCMEC/D3 cells in culture flasks, chamber slides and 
transwell setup were maintained overnight in media con-
taining 1% FBS with no growth factors (referred to as low 
serum media). Next day the cell monolayer was exposed 
to fresh low serum medium of different treatment con-
ditions containing 5.5  mM (normal/control), 35.0  mM 
d-glucose (HG), normal media containing 5% CSE, HG 
media containing 5% CSE. These concentrations are 
based on our previously-published reports.
Cell viability
Extracellular lactate dehydrogenase (LDH) in the media 
increases with plasma membrane damage. The LDH lev-
els in the culture medium were measured after 12 and 
24 h of experimental exposures to various media condi-
tions—5.5 mM control with or without (w/wo) 5% CSE, 
35.0 mM HG w/wo 5% CSE, by a colorimetric enzymatic 
reaction (Pierce LDH cytotoxicity assay kit, Thermo Sci-
entific, Rockford, IL, USA) in accordance with the manu-
facturer guidelines.
Immunofluorescence
HCMEC/D3 cells were seeded in two-well chamber 
slides and grown as mentioned earlier. Cells were fixed 
with 16%, methanol free formaldehyde (diluted 1 in 4 in 
1X PBS; from Polysciences Inc. # 18814) after specified 
experimental exposure duration. This was followed by 
three PBS washes and cell permeabilization using 0.02% 
Triton 100X. After another three PBS washes, fixed 
cells were blocked with 5% goat serum in PBS (blocking 
buffer) at room temperature (RT) for 45  min and incu-
bated overnight at 4°C with primary antibodies prepared 
in blocking buffer. The following day, cells were incubated 
for 1  h at RT with Alexa Fluor® 488 or 555 conjugated 
goat anti-rabbit or anti-mouse antibodies or vice versa, 
respectively (1:1,000) after three washes with PBS. There-
after, cells were rinsed, dried and mounted with DAPI 
in prolonged gold anti-fade mounting media (invitro-
gen). Mounted slides were examined with EVOS digital 
inverted fluorescence microscope after overnight drying. 
Cell slides stained with only secondary antibodies served 
as negative controls.
Western blotting
Cells were lysed using a subcellular protein fractiona-
tion kit for cultured cells (Thermo scientific, # 78840) as 
per manufacturer’s guidelines, such that nuclear, cyto-
solic and membrane fractions were collected. Protein 
quantification was carried out using Pierce BCA Protein 
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Assay Kit (Thermo Scientific, # 23225). Sample prepa-
ration and the entire process was followed as described 
in our previous report [25]. In brief, denatured samples 
(15–30 μg) were subjected to SDS-PAGE (4–15% gradi-
ent gel) and transferred to PVDF membranes for further 
blotting. Western blotting was used to measure the pro-
tein expression of ZO-1, Occludin, PECAM-1, ICAM-1, 
GLUT-1, SGLT-1, and P-gp in cell membrane fraction. 
Nrf-2 protein expression in cytosol vs. nuclear fraction 
was evaluated. Band densities were analyzed by Image 
Studio Lite Ver 3.1 and calculated as fold change over 
control protein expression.
ELISA
Cell culture media from flasks were collected after 24 h 
of exposure to treatment conditions (5.5 mM control w/
wo 5% CSE, 35.0 mM HG w/wo 5% CSE). These cell cul-
ture supernatant samples were then analyzed by Quan-
tikine ELISA kits (R&D systems, Minneapolis, MN, USA) 
for quantitative determination of vascular endothelial 
growth factor (VEGF), interleukin-6 (IL-6) and interleu-
kin-8 (IL-8), according to the manufacturer’s protocol.
BBB integrity
In order to evaluate BBB integrity, our previously-reported 
method was followed [31]. In brief, a mixture of labeled 
dextrans in PBS (FITC ~4  kDa, 8  mg/ml; Cascade Blue 
~10  kDa, 5  mg/ml; and RITC ~70  kDa, 8  mg/ml) were 
added to the luminal compartment of the transwells upon 
treatment exposure of the cells for 24  h. The media was 
sampled from the abluminal compartment (50  µl) and 
replaced with the equal volumes of fresh media to main-
tain appropriate sink conditions. The concentration of 
each fluorescent dye in the sample was determined by 
fluorescent measurements at their specific excitation and 
emission wavelengths. Media samples without dextran and 
that from abluminal compartments of cell free inserts with 
dextran added to the luminal compartment, served as ref-
erences. The permeability measurements were reported 
as percentage of controls. In addition, we measured TEER 
(Ω  cm2) using EVOM 2 (World Precision Instruments, 
Sarasota, FL, USA), as described earlier [40]. Cell free 
inserts were also evaluated for TEER for subtraction.
P‑gp efflux activity
To assess the activity of P-gp, the cellular retention of 
P-gp substrate rhodamine-123 was measured fluorimet-
rically at excitation/emission wavelengths of 485/535 nm. 
The cells were cultured as detailed above and were 
treated for 24  h with 35.0  mM d-glucose (HG), normal 
media containing 5% CSE, HG media containing 5% CSE, 
apart from 5.5  mM (normal/control) exposure. At the 
end of 24 h, cells were washed with cold Hank’s balanced 
salt solution (HBSS) without calcium and magnesium 
(Life Technologies) and incubated on ice with rhoda-
mine123 (10  µg/ml) in efflux buffer for 1  h. The efflux 
buffer consisted of 10  mM HEPES, 1% BSA in EBM-2 
basal medium. Cells were subsequently washed with pre-
warmed HBSS and incubated in efflux buffer at 37°C for 
30  min under gentle agitation. Finally, cells were rinsed 
with ice-cold PBS and lysed with 0.3% triton X-100. The 
fluorescence of cell lysates was measured and normalized 
to protein content of the sample.
Statistical analysis
Data from all experiments were expressed as 
mean  ±  standard deviation (SD) and analyzed by one-
way ANOVA using GraphPad Prism 6 Software Inc. (La 
Jolla, CA, USA). Post hoc multiple comparison tests were 
performed with Tukey’s test. P value <0.05 was consid-
ered statistically significant.
Results
Exposure to hyperglycemia and/or cigarette smoke extract 
does not affect hCMEC/D3 cell viability
Endothelial cell viability was determined by assessing the 
release of LDH into the medium in response to specific 
test culture conditions vs. controls. As shown in Fig-
ure 1a1, b1, 12 and 24 h cell exposure to 5% diluted CSE 
from 3R4F regular cigarettes, 35.0 mM HG media and a 
co-exposure to hyperglycemia and CSE (HG + CSE) did 
not cause any significant cellular toxicity as demonstrated 
by LDH release. Cytotoxicity detection results were fur-
ther confirmed by morphological inspection. Phase con-
trast microscopy images (Figure  1a2, b2) showed that 
hCMEC/D3 cell maintained an intact fully confluent 
monolayer without any loss of contacts between adjacent 
cells despite exposure to CSE, HG or HG + CSE. No dif-
ference was observed following 12 h or 24 h exposure to 
the test conditions vs. controls.
Exposures to hyperglycemia and/or cigarette smoke 
extract impact ZO‑1 protein expression and distribution
Immunofluorescence analysis of BBB endothelial cell 
monolayer revealed an initial increase in ZO-1 expres-
sion (at 12 h) followed by a significant loss of ZO-1 rela-
tive to control (at 24 h) at cell–cell junctions on exposure 
to HG, CSE and HG + CSE. Despite the increase immu-
noreactivity to ZO-1 observed following the initial 12 h 
of exposure to the test conditions, the immunofluores-
cence images revealed a dysregulation in ZO-1 protein 
alignment at cell–cell junction. These results were further 
confirmed by Western blot analysis of the corresponding 
membrane fractions (Figure  2a, b) in which an increase 
in ZO-1 membrane expression due to CSE (p  <  0.05) 
and HG  +  CSE (p  <  0.001) at 12  h was followed by a 
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Figure 1 Effects of hyperglycemic conditions and cigarette smoke extract exposure on hCMEC/D3 cell viability. Lactate dehydrogenase (LDH) 
release, a measure of cytotoxicity from the D3 cell monolayers at 12 h (a) and 24 h (b) following exposure to HG, CSE and HG + CSE conditions 
vs. controls. Data are expressed as mean ± SD (% control). Phase contrast microscopic images (10×, scale 400 µm) of the hCMEC/D3 monolayers 
clearly showed a lack of cell toxicity under the experimental conditions tested above. n = 3 biological replicates.
Figure 2 Exposure to hyperglycemic conditions, cigarette smoke extract and both combined impact expression and distribution of tight junction 
protein ZO-1. a 12 h exposure to CSE and HG + CSE increases ZO-1 expression in HCMEC/D3 as clearly shown by Western blot and immunofluo-
rescence analysis of cell monolayers. However, protein distribution in the membrane was significantly altered. b By contrast to 12 h, 24 h exposure 
reversed the previous effect on ZO-1 expression which appeared to be down-regulated. As clearly shown by immunofluorescence analysis (both 
12 and 24 h), there was a significant additive disruptive effect on ZO-1 distribution when HG and CSE were combined. n = 3–4 biological replicates. 
*p < 0.05, **p < 0.01, ***p < 0.001 vs. control; $p < 0.05 vs. HG.
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decrease of ZO-1 membrane expression at 24 h under the 
same experimental conditions (HG, CSE (p  <  0.01) and 
HG + CSE (p < 0.05). However, under the same experi-
mental conditions occludin expression levels at 12 and 
24 h were largely unchanged when compared to controls 
(data not shown).
Effects of hyperglycemia and/or cigarette smoke extract 
on hCMEC/D3 endothelial monolayer integrity
Vascular endothelial growth factor (VEGF) is known to 
induce angiogenesis as well as cause permeabilization 
of blood vessels [41]. As shown in Figure  3a, CSE and 
HG +  CSE triggered a significant endothelial release of 
VEGF (p  <  0.01 for CSE, p  <  0.001 for HG +  CSE). In 
contrast, HG exposure alone did not elicit any statistically 
significant VEGF release although a modest increase was 
noted. Our data also clearly showed an additive effect 
on VEGF release in cell cultures co-exposed to HG and 
CSE together, with a larger effect than cultures exposed 
to either HG or CSE alone. As expected, alteration of 
ZO-1 protein expression/distribution as well as increase 
in VEGF impacted the integrity of the BBB endothelial 
Figure 3 Effects of hyperglycemic conditions, cigarette smoke extract and both combined exposure on BBB endothelial monolayer integrity. a CSE 
and HG-CSE but not HG elicited the release of VEGF (p < 0.01 for CSE, p < 0.001 for HG-CSE). b HG, CSE and HG + CSE induced a significant decrease 
of trans-endothelial electrical resistance (TEER). This is in agreement with a corresponding increased permeability to dextran molecules Rhod.B-
ITC (70 kDa), Cascade blue (10 kDa) and FITC (3–4 kDa) as shown in c. n = 5 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, 
*****p < 0.00001 vs. control and $p < 0.05, $$p < 0.01, $$$p < 0.001 vs. HG.
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monolayer. This is clearly demonstrated by TEER meas-
urement before (average values were 49.25  ±  7.63 SD; 
47.6  ±  3.36 SD; 47.83  ±  5.52 SD; 50  ±  7.93 SD Ohm.
cm2 for control, HG, CSE and HG + CSE, respectively) 
and after 24 h experimental exposure (50.20 ± 6.05 SD; 
28.00 ±  2.53 SD; 18.67 ±  3.67 SD; 19 ±  1.67 SD Ohm.
cm2 for control, HG, CSE and HG + CSE, respectively); 
and permeability measurement to dextran molecules 
across the endothelial monolayer established on Tran-
swell supports. TEER values decreased significantly after 
24 h of exposure to HG, CSE and HG + CSE (p < 0.0001) 
in comparison to controls (Figure 3b). Note the increased 
paracellular flux (luminal to abluminal) of fluorescent 
dextrans shown in Figure  3c. Increased permeability to 
70 kDa dextran (Rhod.B-ITC) and 10 kDa dextran (Casc 
blue) were noted in transwells exposed to HG, CSE and 
HG  +  CSE although results were statistically signifi-
cant (p  <  0.01) only for the last two conditions. On the 
other hand, permeability to 3–4  KDa, lower molecular 
weight dextran (FITC) was significantly increased when 
compared to controls in all the exposure conditions 
mentioned above. Further, loss of barrier functions was 
considerably more severe in response to HG  +  CSE 
exposure and followed the same pattern observed for the 
release of VEGF.
Exposure to hyperglycemia and/or cigarette smoke extract 
affect expression of glucose transporters in the membrane 
fraction of blood–brain barrier endothelial cells
Western blot analysis of the endothelium membrane 
fractions following 12 h exposure to CSE and HG + CSE 
revealed a significant up-regulation of both sodium 
independent and dependent glucose transporter pro-
teins—GLUT-1 and SGLT-1, respectively (p  <  0.05). 
No significant changes in GLUT-1 and SGLT-1 expres-
sion were noted in hCMEC/D3 cultures exposed to HG 
(Figure  4a1, a2). The effect persisted at 24  h exposure 
wherein GLUT-1 upregulation was significant even in 
HG-exposed cultures (p  <  0.05) (Figure  4b1). By con-
trast, SGLT-1 upregulation was transient and returned to 
baseline levels at 24  h exposure in all tested conditions 
(Figure  4b2). Western blot results were confirmed by 
Figure 4 Hyperglycemic conditions, cigarette smoke extract and both combined affect expression of glucose transporters in membrane fractions 
of BBB endothelial cells. Sodium-independent and dependent glucose transporter proteins- GLUT-1 (a1) and SGLT-1 (a2) were significantly upregu-
lated by CSE and HG + CSE in an additive pattern. GLUT-1 upregulation persisted at 24 h exposure (b1) however, SGLT-1 membrane expression 
returned to levels comparable to that of controls (b2). n = 3–4 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001 vs. control; $p < 0.05 vs. HG 
and #p < 0.05 vs. CSE.
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immunofluorescence analysis revealing similar uptrends 
of GLUT-1 expression.
P‑glycoprotein expression and activity in membrane 
fraction of blood–brain barrier endothelial cells 
is upregulated by co‑exposure to hyperglycemia 
and cigarette smoke extract
As revealed by Western blot analyses of the endothelial 
membrane fractions from hCMEC/D3 cultures exposed 
to HG, CSE and HG + CSE, P-gp expression was upreg-
ulated at both 12 and 24  h in all the tested conditions 
(p < 0.05; see Figure 5a, b) when compared to the corre-
sponding controls. However, the increase in P-gp expres-
sion after 24 h exposure to HG or CSE did not translate 
into a comparable increase of rhodamine 123 efflux. 
The effect became statistically significant only when the 
cell monolayers were co-exposed to both HG and CSE 
(p < 0.05; see Figure 5b).
Hyperglycemia and/or cigarette smoke extract promote 
pro‑inflammatory activity and anti‑oxidant defense 
response mechanisms in hCMEC/D3 endothelial cells
As shown in Figure 6a1, endothelial membrane expres-
sion of platelet endothelial cell adhesion molecule-1 
(PECAM-1) was already up-regulated 12  h following 
exposure to HG and HG + CSE, as compared to con-
trol and CSE. Note the synergistic up-regulation of 
PECAM-1 expression following 12 h HG + CSE expo-
sure when compared to HG and CSE conditions sepa-
rately. The magnitude of the pro-inflammatory effect 
triggered by the tested conditions further increased at 
24  h exposure where not only PECAM-1 overexpres-
sion became significantly higher than controls in all 
tested conditions (p < 0.05; see Figure 6b1), but also in 
HG + CSE vs. CSE and HG alone, thereby showing an 
additive effect. Besides PECAM-1, 12 h exposure to all 
the above mentioned experimental conditions triggered 
a statistically (p  <  0.0001) significant up-regulation of 
intercellular adhesion molecule-1 (ICAM-1) in all the 
experimental conditions when compared to controls. 
In terms of magnitude, the effect was slightly dimin-
ished at 24 h exposure where only CSE and HG + CSE 
elicited a statistically significant effect on ICAM-1 
expression (p  <  0.05; see Figure  6a2, b2). By contrast 
to PECAM-1, ICAM-1 upregulation did not show an 
additive pattern.
ELISA analysis of the cell culture media following 24 h 
exposure to HG, CSE and HG + CSE revealed a signifi-
cant upward trend (p < 0.05, p < 0.0001, and p < 0.0001 
respectively) in the release of interleukin-8 (IL-8) com-
pared to controls (Figure  6c2), which demonstrated an 
additive pattern when HG and CSE stimuli were com-
bined. Interestingly, the release of interleukin-6 (IL-6) 
Figure 5 HCMEC/D3 P-gp protein expression and activity is upregu-
lated by exposure to hyperglycemic conditions, cigarette smoke 
extract and both combined. a P-gp expression in the membrane 
fraction was significantly upregulated following 12 h exposure to HG 
(p < 0.05), CSE (p < 0.01) and HG + CSE (p < 0.05) when compared to 
the corresponding controls. b Effect on membrane P-gp expression 
persisted at 24 h exposure under all tested conditions. However, a 
significant increase in efflux activity was observed only in endothelial 
cultures exposed to HG + CSE. (p < 0.05; n = 4 biological replicates). 
*p < 0.05, **p < 0.01, ***p < 0.001 vs. control.
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Figure 6 Exposure to hyperglycemic conditions, cigarette smoke extract and both combined promotes the pro-inflammatory and anti-oxidant 
defense activation in HCMEC/D3 BBB endothelial cells. a1 PECAM-1 expression in membrane fraction was significantly increased only in endothelial 
cultures following 12 h exposure to HG and HG + CSE. The magnitude of the effect significantly increased at 24 h exposure showing a consist-
ent additive pattern between tested conditions (b1). a2 12 h HG, CSE and HG + CSE triggered upregulation of ICAM-1 membrane fraction. By 
contrast, although statistically significant, the upregulation of ICAM-1 did not show a longitudinal response pattern to the tested conditions (b2). 
c1, c2 Release of IL-6 modestly increased in HG-CSE treated cultures while an additive and more robust increased in IL-8 release was observed 
under the same conditions at 24 h. d Representative Western blot showing the translocation of Nrf-2 from cytosol to nucleus of HCMEC/D3 cells in 
response to the above mentioned tested conditions. The graph bars clearly show the nuclear vs. cytosol ratios of Nrf-2 under the tested conditions. 
n = 3–4 biological replicates. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 vs. control; $p < 0.05, $$p < 0.01, $$$$p < 0.0001 vs. HG and #p < 0.05, 
####p < 0.0001 vs. CSE.
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remained mostly unchanged except for a modest increase 
in HG + CSE culture conditions (Figure 6c1).
Nuclear-factor (erythroid derived 2) related factor-2 
(Nrf2), one of the major transcription factors coopera-
tively regulating the anti-oxidant defense response was 
notably observed to be activated in endothelial cell cul-
tures exposed to HG, CSE and HG  +  CSE. Further as 
shown by the Western blot analysis in Figure  6d there 
is a clear nuclear translocation of Nrf2 in response to all 
tested conditions. However, the effect was most signifi-
cant in cultures exposed to either CSE or HG + CSE even 
when compared to HG alone. This is also evident in the 
graph bar depicting the ratios between nuclear vs. cyto-
sol localization of this transcription factor.
Discussion
Cerebrovascular pathological conditions such as stroke, 
Alzheimer’s, and multiple sclerosis involving a change 
in brain microenvironment are characteristically accom-
panied by BBB dysfunction [20], thereby emphasizing 
the necessity of maintaining a proper barrier function 
and integrity to conserve the brain tissue microenvi-
ronment. As mentioned earlier, both 2DM and TS have 
been considered to increase the chances of developing 
and progressing the above-mentioned cerebrovascular 
pathological conditions [1, 8–10]. Recent findings from 
our laboratory demonstrated that CSE exposure, com-
parable to physiological nicotine plasma concentrations 
of 100 ng/ml as observed in an average chronic smoker, 
induces BBB endothelial dysfunction and a strong inflam-
matory response. This included a down-regulation and 
redistribution of TJ protein expression, an up-regulation 
in expression of adhesion molecules and an increase in 
release of proinflammatory cytokines such as matrix 
metalloproteinase-2 (MMP-2) and IL-6 [25]. On similar 
lines, reports from our lab and others have demonstrated 
an altered expression and distribution of TJ and glucose 
transporter proteins in BBB endothelial cell cultures fol-
lowing exposure to DM like altered hyperglycemic condi-
tions (35.0 mM d-glucose levels) [31].
As a TJ scaffolding protein anchored to the actin 
cytoskeleton, ZO-1 is crucial for the regulation of inter-
endothelial TJ complexes and BBB structural integrity 
[42, 43]. Results from this study demonstrate a progres-
sive down-regulation and disruption of ZO-1 expression/
continuity at cell–cell contacts following 24 h exposure to 
HG, CSE or both, although an initial increase in expres-
sion of ZO-1 in membrane fractions was observed at 12 h 
under CSE conditions (Figure 2). These data further cor-
roborate our previous studies indicating a 50% reduction 
in ZO-1 expression by exposure to CSE alone [25] and a 
marked disruption of ZO-1 bands at cell–cell contacts 
by HG [31]. In addition, diabetes-related hyperglycemia 
significantly suppressed ZO-1 expression in rodent BBB 
[44]. Based on these findings, it is likely that HG down-
regulates ZO-1 expression with an apparent increase 
in its cytosolic redistribution [31]. However, we did not 
observe additive effects on ZO-1 reduction by HG + CSE 
exposure compared to either treatment alone, suggest-
ing a saturated common pathway (Figure  2). Addition-
ally, reduction of ZO-1 expression was accompanied 
by a decreased TEER across endothelial monolayers 
and significant increase in paracellular permeability to 
labeled dextrans in a size-selective manner, especially by 
CSE (Figure 3). This is in agreement with previous find-
ings from our laboratory and others showing a propor-
tionate increase in BBB permeability due to loss of TJ 
proteins [25, 31, 45]. Importantly, HG aggravated the 
CSE-induced BBB permeability of all labeled dextrans, 
thus implicating an exacerbated BBB damage by smok-
ing co-morbid with diabetes. Moreover, as shown in Fig-
ure 3, loss of BBB integrity by CSE could also be plausibly 
explained by an increased endothelial release of VEGF, 
a potent mediator of BBB disruption that was previ-
ously shown to be involved in hyperglycemia–induced 
BBB disruption [31, 46]. Interestingly, our results corre-
late with previous findings [31] by Sajja et al. which have 
also shown only a modest increase of VEGF release from 
hCMEC/D3 monocultures whereas a significant higher 
output of this growth factor was observed in hCMEC/D3 
co-cultures with human astrocytes. This is an additional 
experimental condition we are planning to exploit in 
future along with direct animal experimentation to vali-
date our findings. Further, VEGF blockade restored the 
BBB integrity by preventing the loss of ZO-1 and other 
TJ proteins [47]. Thus, concomitant exposure to HG 
exacerbates CSE-induced BBB damage by potentiating 
VEGF release (Figure 3).
Glucose flux across the BBB is a dynamic phenomenon 
and is majorly mediated by facilitative and insulin-inde-
pendent GLUT-1 (~55  kDa isoform) in response to the 
circulating glucose levels and cerebral metabolic demand 
[28]. In this study, we have shown for the first time that 
CSE exposure alone or concomitant with HG signifi-
cantly increases the membrane expression of GLUT-1 
in hCMEC/D3 cultures and the increase is sustained up 
to 24  h treatment (Figure  4). However, we observed a 
time-dependent effect (delayed onset) of HG on GLUT1 
expression with an overall increase at 24 h but not 12 h 
exposure. Previously, conflicting lines of evidence were 
reported for the effects of hyperglycemia on BBB GLUT1 
and glucose transport [28]. For example, experimental 
models of diabetes revealed a significant repression [48] 
or no change [49] in GLUT1 density and glucose trans-
port at BBB. In this line, our recent findings have demon-
strated unaltered total cellular GLUT1 (unfractionated) 
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levels following 24  h exposure to hyperglycemic condi-
tions in hCMEC/D3 cells [31]. In this study, we examined 
the changes in GLUT1 expression in membrane fractions 
isolated from cells exposed to HG and/or CSE. Given 
the increased membrane GLUT1 and unchanged total 
GLUT1 expression [31], we speculate that HG promotes 
the translocation and membrane deposition of cyto-
solic GLUT1. Additional functional studies are required 
to validate these findings. Nevertheless, our data shows 
a significant additive increase in membrane GLUT1 
expression following combined exposure to HG and CSE, 
which would contribute to elevated levels of oxidative 
stress in BBB endothelium.
Additionally, our results indicate a significant and tran-
sient increase of SGLT-1 in hCMEC/D3 membranes fol-
lowing CSE alone or in combination with HG (Figure 5). 
As previously reported [31], prolonged exposure to HG 
(24 h) did not elicit significant changes in SGLT-1 expres-
sion. This is also in line with current findings showing 
that membrane expression of SGLT-1 return to base-
line levels at 24 h following a transient increased at 12 h. 
Although the relative contribution of SGLT-1 to glu-
cose transport at the BBB is currently unknown, it was 
previously shown that BBB SGLT-1 expression could be 
induced under pathophysiological conditions such as 
stroke [50] and hypoglycemia [31]. Therefore, it is likely 
that CSE-induced increase in SGLT-1 expression (12  h) 
in presence of HG could be mediated by an acute stress-
ful response in hCMEC/D3 cells.
Diabetes-related hyperglycemia was previously 
shown to attenuate the expression of functional P-gp in 
rodent brain, thereby altering the CNS distribution of 
its substrates [51–53]. By contrast, other studies dem-
onstrated a lack of effect [38] or a dramatic increase in 
P-gp expression [37] following hyperglycemia in mouse 
brain endothelial cells. Recently, we have shown that 
acute and chronic hyperglycemia differentially influences 
functional expression of BBB efflux transporters, includ-
ing P-gp where repeated hyperglycemic stimuli over 
3  days caused a significant increase in its efflux activ-
ity [54]. However, the effects of CSE alone and in the 
presence of HG on transporter activity of P-gp, remain 
unknown. Our data indicated a sustained up-regulation 
of membrane-bound P-gp expression by HG or CSE 
exposure following 24  h acute exposure although, no 
additive effects were observed under combined expo-
sure conditions (Figure 5). Interestingly, P-gp activity (as 
measured by rhodamine123 efflux) was increased only 
by HG + CSE co-exposure at 24 h (as opposed to repeti-
tive hits of HG exposure over several days as reported by 
Sajja et  al.), suggesting a possible synergistic effect and 
an increased potential for altered CNS drug disposition 
of P-gp substrates in diabetic smokers [54]. It is also pos-
sible that repetitive stimuli [54] will further enhance this 
effect which we plan to test in future experiments. Given 
the extensive characterization of hCMEC/D3 cell line 
for its applicability to human BBB drug transport stud-
ies and its broad utility for understanding the molecular 
regulation of BBB efflux transporters in vivo [39, 55, 56], 
the findings of our study may hold clinical significance. 
However, in  vivo validation studies will be necessary to 
confirm our results.
Existing evidence associates the role of inflammation 
and oxidative stress with the development of various 
CNS disorders in diabetes as well as chronic smoking. 
Previously we have shown that hyperglycemia induces 
transient up-regulation of inflammatory cell adhesion 
molecules such as VCAM-1 [31]. Similarly in a separate 
study we observed a moderate increase in the expression 
level of PECAM-1 and IL-8 following exposure to CSE 
from 3R4F cigarettes [25]. Herein we observed a signifi-
cant increase of PECAM-1 in the co-exposure conditions 
suggesting an additive effect of HG and CSE. By contrast 
ICAM-1 was upregulated in all the conditions tested 
when compared to controls but no additive effect was 
observed. These results suggest the possibility for leuko-
cyte-endothelial interactions eventually facilitating trans-
migration of circulating white blood cells (WBC) across 
the BBB [57]. This warrants further study in vivo to vali-
date this hypothesis. In addition to vascular endothelial 
molecules, HG potentiated the release of IL-8 by CSE 
also strengthening the hypothesis for an additive inflam-
matory effect between HG and CSE prodromal to a pos-
sible neuroinflammatory disorder [58].
Nrf2 is master regulator and redox-sensitive tran-
scription factor that has a pleiotropic role in mediat-
ing cellular antioxidant responses [59]. In fact we have 
recently shown the neuroprotective role of Nrf2 in regu-
lating and maintaining BBB integrity [60]. As previously 
reported by our group hyperglycemia does not overall 
affect the total expression level of Nrf2 [31], however, 
HG modulates its distribution in the cells when we ana-
lyzed and compared the nuclear vs. cytosolic content. 
As shown in Figure 6d CSE exposure markedly elevated 
the nuclear/cytoplasmic ratio of Nrf2 suggesting activa-
tion of the antioxidant pathways. This effect was further 
enhanced by HG despite eliciting nuclear translocation 
of Nrf2 to a lesser extent when compared to CSE or 
HG + CSE. This latter implies the existence of a coop-
erative effect in term of cellular oxidative response acti-
vation. This in the long term can be more detrimental to 
BBB integrity if the oxidative stimuli overcome the pro-
tective antioxidant mechanisms of the BBB endothelial 
cells.
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Conclusions
Hyperglycemia exacerbates the pathological impact 
of cigarette smoke extract on BBB functional integ-
rity in  vitro, possibly through activation of endothe-
lial inflammatory and oxidative stress responses. These 
hypotheses, however, need to be further validated in vivo 
to fully assess the pathophysiological effects in relation to 
the cerebrovascular system and onset of neuroinflamma-
tory disorders.
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